China Biologic Products (NASDAQ:CBPO) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
A number of other equities research analysts have also issued reports on CBPO. ValuEngine raised China Biologic Products from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Credit Suisse Group lowered China Biologic Products from an “outperform” rating to a “neutral” rating in a research report on Monday, August 6th. BidaskClub lowered China Biologic Products from a “hold” rating to a “sell” rating in a research report on Saturday, August 18th. Finally, Morgan Stanley lowered China Biologic Products from an “overweight” rating to an “equal weight” rating and set a $84.00 price target on the stock. in a research report on Monday. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $95.33.
China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.13). The company had revenue of $119.10 million for the quarter, compared to analyst estimates of $122.00 million. China Biologic Products had a return on equity of 11.44% and a net margin of 15.50%. The firm’s revenue for the quarter was up 19.6% on a year-over-year basis. During the same period last year, the firm earned $1.32 earnings per share. As a group, equities analysts anticipate that China Biologic Products will post 3.43 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of CBPO. UBS Group AG raised its position in China Biologic Products by 84.1% during the first quarter. UBS Group AG now owns 41,699 shares of the biopharmaceutical company’s stock valued at $3,377,000 after buying an additional 19,054 shares during the period. Baillie Gifford & Co. raised its position in China Biologic Products by 0.7% during the second quarter. Baillie Gifford & Co. now owns 1,347,282 shares of the biopharmaceutical company’s stock valued at $133,826,000 after buying an additional 8,968 shares during the period. Parametrica Management Ltd purchased a new position in China Biologic Products in the second quarter valued at about $386,000. Kassirer Asset Management Corp purchased a new position in China Biologic Products in the second quarter valued at about $596,000. Finally, First Trust Advisors LP purchased a new position in China Biologic Products in the second quarter valued at about $3,213,000. 44.12% of the stock is currently owned by hedge funds and other institutional investors.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.